Shareholder Alert: The Ademi Firm investigates whether Mersana Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders

Core Insights - Mersana is under investigation for potential breaches of fiduciary duty related to its transaction with Day One Biopharmaceuticals [1][3] Transaction Details - Mersana shareholders will receive $25.00 per share in cash, with potential contingent value rights payments of up to $30.25 per share, leading to a total equity value of approximately $129 million at closing and a total deal value of up to approximately $285 million if all milestones are met [2] - The contingent payments are linked to clinical development, regulatory, and commercial milestones for Mersana's B7-H4-directed antibody-drug conjugate Emi-Le [2] Governance Concerns - Mersana insiders are set to receive substantial benefits from change of control arrangements, raising concerns about the fairness of the transaction [3] - The transaction agreement imposes significant penalties on Mersana for accepting competing bids, which may indicate a lack of fiduciary responsibility by the board of directors [3]